Patently absurd

If the Supreme Court rejecting Swiss pharmaceuticals firm Novartis’s application for a patent for its anti-cancer drug Glivec earlier this week wasn’t devastating enough for pharma MNCs, the Delhi High Court’s refusal to grant relief to US firm Merck Sharp & Dohme on Friday showed up patently problematic gaps in India’s pharmaceuticals regulatory system—Merck had asked the court to stop local Indian firm Glenmark Pharmaceuticals from selling versions of its patented drugs since the patent was still in force.

Read Full Story>>